Rebecca
Translator — German
Articles translated into German by Rebecca
- How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain
- Understanding expansions at the single cell level
- Huntington's Disease Therapeutics Conference 2024 - Day 3
- Huntington's Disease Therapeutics Conference 2024 - Day 1
- Huntington's Disease Therapeutics Conference 2024 - Day 2
- CRISPR-based drugs: one giant leap for mankind
- Steady progress from uniQure - promising data to end the year
- Putting it in print: GENERATION HD1 study results published
- Regulating repetition: Gaining control of CAG repeats could slow progression of Huntington’s disease
- Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
- Getting to the Root of Huntington's Disease: A Plant-Based Approach
- Could halting CAG expansions be a new treatment for HD?
- Drug to treat movement symptoms of HD approved by FDA
- Youthful competitors: young brain cells oust the old
- Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
- Roche Phase II GENERATION HD2 study underway
- Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
- uniQure gets the green light to resume testing HD gene therapy
- Update on the PTC Therapeutics PIVOT-HD Trial
- Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
- Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
- Hereditary Disease Foundation (HDF) conference 2022 – Day 4
- Hereditary Disease Foundation (HDF) conference 2022 – Day 3
- Hereditary Disease Foundation (HDF) conference 2022 – Day 2
- Hereditary Disease Foundation (HDF) conference 2022 – Day 1
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Huntington’s disease therapeutics conference 2022 - Day 1
- Revisiting vitamin therapy for HD
- A spoonful of branaplam helps the huntingtin go down
- Oral drug may change the story for huntingtin lowering
- Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
- “Seeing” the toxic huntingtin protein in people with HD
- KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
- Real talk: Q&A with Roche about GENERATION-HD1
- Updates from the EHDN Meeting 2021
- Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing
- Unpacking recent gene therapy press
- Does blood hold the key to testing treatments earlier in HD patients?
- A first for CRISPR gene editing could have wider applications for human disease
- Scientists identify precisely how pridopidine works in models of Huntington’s disease
- Huntington’s disease clinical trial round up
- Huntington's disease therapeutics conference 2021 - Day 3
- Huntington's disease therapeutics conference 2021 - Day 2
- Huntington’s disease therapeutics conference 2021 - Day 1
- Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
- Sad News from Roche and Ionis - ASO Trial Halted Early
- GPR52: Exploring a new way to lower huntingtin
- Uncovering the dark side of DNA repair to design HD treatments
- Screening the entire genome for new drug targets for HD
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1
- Treatment for neurological disorder could be repurposed for Huntington’s disease patients
- Updates from the EHDN Plenary Meeting 2020
- Sad news from the SIGNAL study: pepinemab does not influence HD symptoms
- When genes are unstable: targeting somatic instability in HD
- Working as a team: Changes in brain development mean some brain regions may be slacking off
- Caution urged for the use of gene-editing technology CRISPR
- HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk
- Changing jobs: converting other cell types into neurons
- HD Young Adult Study defines the sweet spot: symptom-free with measurable changes
- Fountain of youth: HTT protein repairs neurons by maintaining youthful state
- Huntington’s disease therapeutics conference 2020 - Day 3
- Huntington’s disease therapeutics conference 2020 - Day 2
- New molecule can reverse the Huntington's disease mutation in lab models
- Huntington’s disease therapeutics conference 2020 - Day 1
- The third dimension: using minibrains to understand brain development changes in HD
- Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
- Could molecular handcuffs lower the protein that causes Huntington's disease?
- Exciting new Huntingtin lowering tool described
- Details emerge of first Huntington’s disease gene therapy clinical trial
- Fresh Updates from First Huntingtin Lowering Study Publication
- An Updated Trial Design for Roche's Huntingtin Lowering Trial
- When interrupting is good: genetic hiccups that protect against Huntington's disease
- Huntington's disease therapeutics conference 2019 - Day 3
- Huntington's disease therapeutics conference 2019 - Day 2
- Huntington's disease therapeutics conference 2019 - Day 1
- Huntington's disease goes viral as UniQure inches ahead in gene therapy race
- Advances on many fronts in the battle against the protein that causes Huntington's disease
- HDSA FAQ on the Roche/Genentech RG6042 program
- Kids sometimes get Huntington’s disease too
- Roche announces details of its 'pivotal' huntingtin-lowering study
- Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
- HDBuzz Enrolls in Enroll-HD
- First Dolly, now Piglet; a new Huntington’s disease pig knock-in model confirmed
- New collaboration seeks to speed Huntington's disease drug licensing
- HDSA’s Q&A on the latest huntingtin-lowering update from Ionis and Roche
- Exciting Experiments in "Open Science" by Huntington's Researchers
- The structure of the protein that causes Huntington's disease, revealed
- Huntington's disease therapeutics conference 2018 - day 3
- Huntington's disease therapeutics conference 2018 - day 2
- Huntington's disease therapeutics conference 2018 - day 1
- An early role for the Huntington's disease gene – but don't believe all the headlines
- New interest in an old target
- Ask the expert: Q&A on the huntingtin-lowering trial program
- Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
- Switch off the genome editor when you’re done
- A new way of thinking about trials to prevent Huntington's disease
- New roles for huntingtin: removing a healthy protein to understand its function
- Precision huntingtin-lowering drug trials target the mutant protein
- A step forward for gene editing: CRISPR-Cas9 and HD
- New study reveals a potential HD biomarker
- Has a "wonder drug" for dementia been discovered? (Spoiler alert: no.)
- Enemy at the gates – huntingtin disrupts nuclear transport
- FDA approves a new drug for symptoms of Huntington's disease
- Weeding out the truth: can cannabis improve Huntington’s?
- Sheep leading the flock: metabolism and biomarkers in HD